Nathanael S. Gray
Molecular Biology · 2000–2021
A researcher in the Science corpus: 31 papers; trusts 3 researchers and is trusted by 9 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 393 citations into it; #4,483 of 17,773 by trust here, #799 by citations
- Oncology — 116 citations into it; #1,046 of 1,698 by trust here, #355 by citations
- Hematology — 75 citations into it; #63 of 225 by trust here, #108 by citations
- Genetics — 70 citations into it
Whom Nathanael S. Gray trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts Nathanael S. Gray overall
Papers from Nathanael S. Gray's perspective
Ordered by how strongly the researchers Nathanael S. Gray trusts endorse each paper. Same corpus, a different order for every researcher.
- Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. (Science)
- The Protein Kinase Complement of the Human Genome (Science)
- Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. (Cell)
- mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. (Cell)
- Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. (Molecules and Cells)
- A small molecule–kinase interaction map for clinical kinase inhibitors (Nature Biotechnology)
- A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) (Cancer Research)
- Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). (Cancer Research)
- Model-based Analysis of ChIP-Seq (MACS)
- mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. (Cancer Research)
Their papers
- An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1* (2009) — 1,819 citations
- Systematic identification of genomic markers of drug sensitivity in cancer cells (2012) — 2,417 citations
- The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling (2011) — 1,097 citations
- DEPTOR is an mTOR Inhibitor Whose Frequent Overexpression in Multiple Myeloma Cells Promotes their Survival (2009) — 1,212 citations
- Targeting cancer with small molecule kinase inhibitors (2009) — 2,565 citations
- A unifying model for mTORC1-mediated regulation of mRNA translation (2012) — 1,466 citations
- Targeting transcription regulation in cancer with a covalent CDK7 inhibitor (2014) — 793 citations
- A Landscape of Pharmacogenomic Interactions in Cancer (2016) — 1,831 citations
- Developing irreversible inhibitors of the protein kinase cysteinome (2013) — 612 citations
- Kinase inhibitors: the road ahead (2018) — 809 citations
- A chemical switch for inhibitor-sensitive alleles of any protein kinase (2000) — 1,081 citations
- A Next Generation Connectivity Map: L1000 platform and the first 1,000,000 profiles (2017) — 2,985 citations
- The promise and peril of chemical probes (2015) — 739 citations
- Activating mutations in ALK provide a therapeutic target in neuroblastoma (2008) — 895 citations
- The Library of Integrated Network-based Cellular Signatures (LINCS) NIH Program: System-level Cataloging of Human Cells Response to Perturbations (2017) — 380 citations
- The dTAG system for immediate and target-specific protein degradation (2018) — 886 citations
- YY1 Is a Structural Regulator of Enhancer-Promoter Loops (2017) — 886 citations
- Sphingosine 1-Phosphate (S1P) Receptor Subtypes S1P1 and S1P3, Respectively, Regulate Lymphocyte Recirculation and Heart Rate* (2004) — 603 citations
- MEK1 mutations confer resistance to MEK and B-RAF inhibition (2009) — 656 citations
- Novel mutant-selective EGFR kinase inhibitors against EGFR T790M (2009) — 979 citations